Upon joining the study, participants are randomly assigned to receive either the medication ianalumab or a placebo. Both are administered as a subcutaneous injection using a pre-filled syringe.

The initial treatment involves the use of high-dose corticosteroids and mycophenolic acid (MPA) as part of the standard-of-care therapy for lupus nephritis. This treatment should be started before or on the day of randomization.

Participants receive the assigned treatment, either ianalumab or placebo, in combination with standard-of-care therapy. The treatment is administered regularly as per the study protocol.

The goal is to achieve a stable complete renal response by Week 72, which involves maintaining kidney function and reducing protein levels in the urine.

Throughout the study, participants undergo regular monitoring to assess the effectiveness and safety of the treatment. This includes measuring the concentration of ianalumab in the blood and checking for any antibodies that may develop against the medication.

Participants are also monitored for any adverse events or changes in vital signs and laboratory measurements.

The primary goal is to evaluate the incidence of stable complete renal response at Week 72. Participants who discontinue treatment before this time or require higher doses of corticosteroids are considered non-responders.

Secondary evaluations include measuring the time to achieve a significant reduction in protein levels in the urine and assessing overall response rates at Week 48.

The study is expected to conclude by July 2030. Participants will have completed all required assessments and treatments by this time.

Final evaluations will determine the long-term effectiveness and safety of ianalumab in treating lupus nephritis.